Current perspectives on co-morbid depression and multiple sclerosis

References

• Marrie RA, Reingold S, Cohen J, et al. The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review. Mult Scler. 2015;21(3):305–317.
   PubMed Web of Science ®Google Scholar
• Boeschoten RE, Braamse AMJ, Beekman ATF, et al. Prevalence of depression and anxiety in multiple sclerosis: a systematic review and meta-analysis. J Neurol Sci. 2017;372:331–341.
   PubMed Web of Science ®Google Scholar
• Brønnum-Hansen H, Stenager E, Stenager EN, et al. Suicide among Danes with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2005;76:1457–1459.
   PubMed Web of Science ®Google Scholar
• Brenner P, Burkill S, Jokinen J, et al. Multiple sclerosis and risk of attempted and completed suicide - a cohort study. Eur J Neurol. 2016;23(8):1329–1336.
   PubMed Web of Science ®Google Scholar
• Erlangsen A, Stenager E, Conwell Y, et al. association between neurological disorders and death by suicide in Denmark. JAMA. 2020;323(5):444–454.
   PubMed Web of Science ®Google Scholar
• McKay KA, Tremlett H, Fisk JD, et al. Psychiatric comorbidity is associated with disability progression in multiple sclerosis. Neurology. 2018;90(15):e1316–e1323.
   PubMed Web of Science ®Google Scholar
• Binzer S, McKay KA, Brenner P, et al. Disability worsening among persons with multiple sclerosis and depression: A Swedish cohort study. Neurology. 2019;93(24):e2216–e2223.
   PubMed Web of Science ®Google Scholar
• Disanto G, Zecca C, MacLachlan S, et al. Prodromal symptoms of multiple sclerosis in primary care. Ann Neurol. 2018;83(6):1162–1173.
   PubMed Web of Science ®Google Scholar
• Wijnands JMA, Kingwell E, Zhu F, et al. Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study. Lancet Neurol. 2017;16(6):445–451.
   PubMed Web of Science ®Google Scholar
• Yusuf FLA, Ng BC, Wijnands JMA, et al. A systematic review of morbidities suggestive of the multiple sclerosis prodrome. Expert Rev Neurother. 2020;1–21.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5). Washington DC. American Psychiatric Association. 5 ed ed. Washington DC: American Psychiatric Publishing; 2013.
   Google Scholar
• Berrigan LI, Fisk JD, Patten SB, et al. Health-related quality of life in multiple sclerosis: direct and indirect effects of comorbidity. Neurology. 2016;86(15):1417–1424.
   Google Scholar
• Lobentanz IS, Asenbaum S, Vass K, et al. Factors influencing quality of life in multiple sclerosis: disability, depressive mood, fatigue and sleep quality. Acta Neurol Scand. 2004;110:6–13.
   PubMed Web of Science ®Google Scholar
• Ferrari AJ, Charlson FJ, Norman RE, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med. 2013;10(11):e1001547.
   PubMed Web of Science ®Google Scholar
• Berzins SA, Bulloch AG, Burton JM, et al. Determinants and incidence of depression in multiple sclerosis: A prospective cohort study. J Psychosom Res. 2017;99:169–176.
   PubMed Web of Science ®Google Scholar
• Pakenham KI. Adjustment to multiple sclerosis: application of a stress and coping model. Health Psychol. 1999;18(4):383–392.
   PubMed Web of Science ®Google Scholar
• Feinstein A, Magalhaes S, Richard JF, et al. The link between multiple sclerosis and depression. Nat Rev Neurol. 2014;10(9):507–517.
   PubMed Web of Science ®Google Scholar
• Mohr DC, Goodkin DE, Likosky W, et al. Treatment of depression improves adherence to interferon b-1b therapy for multiple sclerosis. Arch Neurol. 1997;54:531–533.
   PubMed Web of Science ®Google Scholar
• Tarrants M, Oleen-Burkey M, Castelli-Haley J, et al. The impact of comorbid depression on adherence to therapy for multiple sclerosis. Mult Scler Int. 2011;2011:271321.
   PubMedGoogle Scholar
• Ploughman M, Wallack EM, Chatterjee T, et al. Under-treated depression negatively impacts lifestyle behaviors, participation and health-related quality of life among older people with multiple sclerosis. Mult Scler Relat Disord. 2020;40:101919.
   PubMed Web of Science ®Google Scholar
• Koch MW, Patten S, Berzins S, et al. Depression in multiple sclerosis: a long-term longitudinal study. Mult Scler. 2015;21(1):76–82.
   PubMed Web of Science ®Google Scholar
• Patten SB, Williams JVA, Lavorato DH, et al. Perceived Stigma among recipients of mental health care in the general canadian population. Can J Psychiat. 2016;61(8):480–488.
   PubMed Web of Science ®Google Scholar
• Patten SB, Williams JV, Lavorato DH, et al. Patterns of association of chronic medical conditions and major depression. Epidemiol Psychiatr Sci. 2016;27(1):42–50.
   Web of Science ®Google Scholar
• Patten SB, Beck CA, Kassam A, et al. Long-term medical conditions and major depression: strength of association for specific conditions in the general population. Can J Psychiatry. 2005;50:195–202.
   PubMed Web of Science ®Google Scholar
• Vanderweele TJ, Robins JM. The identification of synergism in the sufficient-component-cause framework. Epidemiology. 2007;18(3):329–339.
   PubMed Web of Science ®Google Scholar
• Rothman KJ, Greenland S, Poole C, et al. Causation and causal inference. In: Rothman KJ, Greenland S, Lash TL, editors. Modern Epidemiology. 3 ed ed. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 5–31.
   Google Scholar
• Rothman KJ. Causes. Am J Epidemiol. 1976;104(6):587–592.
   PubMed Web of Science ®Google Scholar
• Feinstein A, O’Connor P, Akbar N, et al. Diffusion tensor imaging abnormalities in depressed multiple sclerosis patients. Mult Scler. 2010;16(2):189–196.
   PubMed Web of Science ®Google Scholar
• Lamb K, Pies R, Zisook S. The bereavement exclusion for the diagnosis of major depression: to be, or not to be. Psychiatry (Edgmont). 2010;7(7):19–25.
   PubMedGoogle Scholar
• Wakefield JC, Schmitz MF, First MB, et al. Extending the bereavement exclusion for major depression to other losses. Arch Gen Psychiatry. 2007;64:433–440.
   PubMed Web of Science ®Google Scholar
• Kendler KS, Myers J, Zisook S. Does bereavement-related major depression differ from major depression associated with other stressful life events? Am J Psychiatry. 2008;165(11):1449–1455.
   PubMed Web of Science ®Google Scholar
• Spitzer RL. Harmful dysfunction and the DSM definition of mental disorder. J Abn Psychol. 1999;108:430–432.
   PubMed Web of Science ®Google Scholar
• Wakefield JC, First MB. The importance and limits of harm in identifying mental disorder. Can J Psychiatry. 2013;58(11):618–621.
   PubMed Web of Science ®Google Scholar
• Wakefield JC. The concept of mental disorder. On the boundary between biological facts and social values. Am Psychologist. 1992;47:373–388.
   PubMed Web of Science ®Google Scholar
• Wakefield JC, First MB. Clarifying the boundary between normality and disorder: a fundamental conceptual challenge for psychiatry. Can J Psychiatry. 2013;58(11):603–605.
   PubMed Web of Science ®Google Scholar
• Mohr DC, Goodkin DE, Likosky W, et al. Identification of Beck Depression Inventory items related to multiple sclerosis. J Behav Med. 1997;20:407–414.
   PubMed Web of Science ®Google Scholar
• Snaith RP, Zigmond AS. The hospital anxiety and depression scale. Br Med J Clin Res Ed. 1986;292:344.
   PubMed Web of Science ®Google Scholar
• Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:53–63.
   Web of Science ®Google Scholar
• Goldman Consensus Group. The Goldman Consensus Statement on Mood Disorders in Multiple Sclerosis. Mult Scler. 2005;11:328–337.
   PubMed Web of Science ®Google Scholar
• Patten SB, Berzins S, Metz LM. Challenges in screening for depression in multiple sclerosis. Mult Scler. 2010;16(11):1406–1411.
   PubMed Web of Science ®Google Scholar
• Lam RW, Kennedy SH. STAR*D and Measurement-Based Care for Depression: don’t Toss Out the Baby! Can J Psychiatry. 2015;60(1):6–8.
   PubMed Web of Science ®Google Scholar
• Fortney JC, Unutzer J, Wrenn G, et al. A Tipping Point for Measurement-Based Care. Focus (Am Psychiatr Publ). 2018;16(3):341–350.
   PubMedGoogle Scholar
• Sjonnesen K, Berzins S, Fiest KM, et al. Evaluation of the 9-item Patient Health Questionnaire (PHQ-9) as an assessment instrument for symptoms of depression in patients with multiple sclerosis. PostgradMed. 2012;124(5):69–77.
   PubMed Web of Science ®Google Scholar
• First M, Spitzer R, Gibbon M, et al. Structured clinical interview for DSM-IV Axis I disorders. Research version, non-patient edition (SCID-I/NP). New York: New York State Psychiatric Institute; 1997.
   Google Scholar
• Patten SB, Burton JM, Fiest KM, et al. Validity of four screening scales for major depression in MS. Mult Scler. 2015;21:1064–1071.
   PubMed Web of Science ®Google Scholar
• Amtmann D, Kim J, Chung H, et al. Comparing CESD-10, PHQ-9, and PROMIS depression instruments in individuals with multiple sclerosis. Rehabil Psychol. 2014;59(2):220–229.
   PubMed Web of Science ®Google Scholar
• Kroenke K, Spitzer RL. The PHQ-9: A New Depression Diagnostic and Severity Measure. Psychiatr Ann. 2002;32:1–7.
   Web of Science ®Google Scholar
• Patrick S, Connick P. Psychometric properties of the PHQ-9 depression scale in people with multiple sclerosis: A systematic review. PloS One. 2019;14(2):e0197943.
   PubMed Web of Science ®Google Scholar
• Hasselmann H, Bellmann-Strobl J, Ricken R, et al. Characterizing the phenotype of multiple sclerosis-associated depression in comparison with idiopathic major depression. Mult Scler. 2016;22(11):1476–1484.
   PubMed Web of Science ®Google Scholar
• Work SS, Colamonico JA, Bradley WG, et al. Pseudobulbar affect: an under-recognized and under-treated neurological disorder. Adv Ther. 2011;28(7):586–601.
   PubMed Web of Science ®Google Scholar
• Minden SL, Feinstein A, Kalb RC, et al. Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82(2):174–181.
   PubMed Web of Science ®Google Scholar
• Feinstein A. The neuropsychiatry of multiple sclerosis. Can J Psychiatry. 2004;49:157–163.
   PubMed Web of Science ®Google Scholar
• Feinstein A, Feinstein K, Gray T, et al. The prevalence and neurobehavioural correlates of pathological laughter and crying in multiple sclerosis. Arch Neurol. 1997;54:1116–1121.
   PubMed Web of Science ®Google Scholar
• Schiffer RB, Herndon RM, Rudick RA. Treatment of pathological laughing and weeping with amitriptyline. New Eng J Med. 1985;312:1480–1482.
   PubMed Web of Science ®Google Scholar
• Ahmed A, Simmons Z. Pseudobulbar affect: prevalence and management. Ther Clin Risk Manag. 2013;9:483–489.
   PubMed Web of Science ®Google Scholar
• Carta MG, Balestrieri M, Murru A, et al. Adjustment Disorder: epidemiology, diagnosis and treatment. Clin Pract Epidemiol Ment Health. 2009;5:15.
   PubMedGoogle Scholar
• Minden SL, Orav J, Schildkraut JJ. Hypomanic reactions to ACTH and prednisone treatment for multiple sclerosis. Neurology. 1988;38:1631–1634.
   PubMed Web of Science ®Google Scholar
• Morrow SA, Barr J, Rosehart H, et al. Depression and hypomania symptoms are associated with high dose corticosteroids treatment for MS relapses. J Affect Disord. 2015;187:142–146.
   PubMed Web of Science ®Google Scholar
• Patten SB, Neutel CI. Corticosteroid-induced adverse psychiatric effects. Incidence, diagnosis and management. Drug Saf. 2000;22:111–122.
   PubMed Web of Science ®Google Scholar
• Klapper JA. Interferon beta treatment of multiple sclerosis. Neurology. 1994;44:188.
   PubMed Web of Science ®Google Scholar
• Patten SB, Metz LM. Interferon b-1a and depression in relapsing-remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial. Mult Scler. 2001;7:243–248.
   PubMed Web of Science ®Google Scholar
• Feinstein A. Multiple sclerosis, disease modifying treatments and depression: A critical methodological review. Mult Scler. 2000;6(5):343–348.
   PubMedGoogle Scholar
• Alba Pale L, Leon Caballero J, Samso Buxareu B, et al. Systematic review of depression in patients with multiple sclerosis and its relationship to interferon beta treatment. Mult Scler Relat Disord. 2017;17:138–143.
   PubMed Web of Science ®Google Scholar
• Kim S, Foley FW, Picone MA, et al. Depression levels and interferon treatment in people with multiple sclerosis. Int J MS Care. 2012;14(1):10–16.
   PubMedGoogle Scholar
• Hunter SF, Agius M, Miller DM, et al. Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: an analysis from the EPOC (Evaluate Patient OutComes) trial. J Neurol Sci. 2016;365:190–198.
   PubMed Web of Science ®Google Scholar
• Montalban X, Comi G, O’Connor P, et al. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study. Mult Scler. 2011;17(11):1341–1350.
   PubMed Web of Science ®Google Scholar
• Gasim M, Bernstein CN, Graff LA, et al. Adverse psychiatric effects of disease-modifying therapies in multiple Sclerosis: A systematic review. Mult Scler Relat Disord. 2018;26:124–156.
   PubMed Web of Science ®Google Scholar
• Koch MW, Glazenborg A, Uyttenboogaart M, et al. Pharmacologic treatment of depression in multiple sclerosis. Cochrane Database Syst Rev. 2011;2:CD007295. DOI: 110.1002/14651858.CD007295.pub2
   PubMed Web of Science ®Google Scholar
• Manning KJ. Hippocampal Neuroinflammation and Depression: relevance to Multiple Sclerosis and Other Neuropsychiatric Illnesses. Biol Psychiatry. 2016;80(1):e1–2.
   PubMed Web of Science ®Google Scholar
• Schiffer RB, Wineman NM. Antidepressant pharmacotherapy of depression associated with multiple sclerosis. Am J Psychiatry. 1990;147(11):1493–1497.
   PubMed Web of Science ®Google Scholar
• Mohr DC, Boudewyn AC, Goodkin DE, et al. Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J Cons Clin Psychol. 2001;69:942–949.
   PubMed Web of Science ®Google Scholar
• Ehde DM, Kraft GH, Chwastiak L, et al. Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis. Gen Hosp Psychiatry. 2008;30:40–48.
   PubMed Web of Science ®Google Scholar
• Solaro C, Bergamaschi R, Rezzani C, et al. Duloxetine is effective in treating depression in multiple sclerosis patients: an open-label multicenter study. Clin Neuropharmacol. 2013;36(4):114–116.
   PubMed Web of Science ®Google Scholar
• Barak Y, Ur E, Achiron A. Moclobemide treatment in multiple sclerosis patients with comorbid depression: an open-label safety trial. J Neuropsychiatry Clin Neurosci. 1999;11:271–273.
   PubMed Web of Science ®Google Scholar
• Scott TF, Nussbaum P, McConnell H, et al. Measurement of treatment response to sertraline in depressed multiple sclerosis patients using the Carrol scale. Neurol Res. 1995;17:421–422.
   PubMed Web of Science ®Google Scholar
• Nathoo N, Mackie A. Treating depression in multiple sclerosis with antidepressants: A brief review of clinical trials and exploration of clinical symptoms to guide treatment decisions. Mult Scler Relat Disord. 2017;18:177–180.
   PubMed Web of Science ®Google Scholar
• Mura G, Moro MF, Patten SB, et al. Exercise as an add-on strategy for the treatment of major depressive disorder: a systematic review. CNS Spectr. 2014;19(6):496–508.
   PubMed Web of Science ®Google Scholar
• Dalgas U, Stenager E, Sloth M, et al. The effect of exercise on depressive symptoms in multiple sclerosis based on a meta-analysis and critical review of the literature. Eur J Neurol. 2015;22(3):443–e34.
   PubMed Web of Science ®Google Scholar
• Fiest KM, Walker JR, Bernstein CN, et al. Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis. Mult Scler Relat Disord. 2016;5:12–26.
   PubMed Web of Science ®Google Scholar
• Furukawa TA, Noma H, Caldwell DM, et al. Waiting list may be a nocebo condition in psychotherapy trials: a contribution from network meta-analysis. Acta Psychiatr Scand. 2014;130(3):181–192.
   PubMed Web of Science ®Google Scholar
• Hind D, O’Cathain A, Cooper CL, et al. The acceptability of computerised cognitive behavioural therapy for the treatment of depression in people with chronic physical disease: a qualitative study of people with multiple sclerosis. Psychol Health. 2010;25(6):699–712.
   PubMed Web of Science ®Google Scholar
• Mohr DC, Hart SL, Julian L, et al. Telephone-administered psychotherapy for depression. Arch Gen Psychiatry. 2005;62:1007–1014.
   PubMed Web of Science ®Google Scholar
• Boeschoten RE, Dekker J, Uitdehaag BM, et al. Internet-based treatment for depression in multiple sclerosis: A randomized controlled trial. Mult Scler. 2017;23(8):1112–1122.
   PubMed Web of Science ®Google Scholar
• Fischer A, Schroder J, Vettorazzi E, et al. An online programme to reduce depression in patients with multiple sclerosis: a randomised controlled trial. Lancet Psychiatry. 2015;2(3):217–223.
   PubMed Web of Science ®Google Scholar
• Wright JH, Owen JJ, Richards D, et al. Computer-assisted cognitive-behavior therapy for depression: a systematic review and meta-analysis. J Clin Psychiatry. 2019;80(2):18r12188.
   PubMed Web of Science ®Google Scholar